| Literature DB >> 24723366 |
Tamsin J Garrod1, Branka Grubor-Bauk, Tessa Gargett, Yanrui Li, Darren S Miller, Wenbo Yu, Lee Major, Christopher J Burrell, Steven Wesselingh, Andreas Suhrbier, Eric J Gowans.
Abstract
Traditional vaccine strategies are inefficient against challenge with complex pathogens including HIV; therefore, novel vaccine technologies are required. DNA vaccines are attractive as they are relatively cheap and easy to manufacture, but a major limitation has been their lack of immunogenicity in humans, which may be overcome with the incorporation of an adjuvant. HSP70 is a recognised damage-associated molecular pattern, which is a potential adjuvant. We investigated the immunogenicity of a DNA vaccine encoding HIV gag and HSP70; the latter was genetically modified to produce cytoplasmic, secreted or membrane-bound HSP70, the expression of which was controlled by an independent promoter. The DNA was administered to C57BL/6 mice to evaluate gag-specific T-cell responses. Our results demonstrated the ability of membrane-bound and secreted HSP70 to significantly enhance gag-specific T-cell responses and increase the breadth of T-cell responses to include subdominant epitopes. Membrane-bound or secreted HSP70 also significantly improved the multifunctionality of HIV-specific T cells and T-cell proliferation, which is important for maintaining T-cell integrity. Most importantly, the inclusion of membrane-bound HSP70, secreted HSP70 or a combination significantly increased protection in mice challenged with EcoHIV, a chimeric virus that replicates in mouse leukocytes in vivo.Entities:
Keywords: Adjuvant; DNA vaccines; HSP70
Mesh:
Substances:
Year: 2014 PMID: 24723366 DOI: 10.1002/eji.201343983
Source DB: PubMed Journal: Eur J Immunol ISSN: 0014-2980 Impact factor: 5.532